Clinical trials: Etoposide, completed
Peripheral T-cell Lymphoma
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
This is a single center, open-label, phase I trial with a standard 3+3 dose escalation schema to identify the maximum tolerated dose (MTD) of selinexor when combined with ICE.
- Trial name
- NCT03212937
- Testing
- Selinexor, ICE Chemotherapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- National Cancer Centre, Singapore
Fallopian Tube Cancer, Ovarian Cancer
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003967
- Testing
- etoposide, topotecan hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002565
- Testing
- bleomycin sulfate, CHOP regimen, cisplatin
- Where
- 3 sites in United States, Brazil and 1 more
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003401
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Unresectable Locally Advanced NSCLC
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally…
- Trial name
- NCT00682383
- Testing
- Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002494
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- 23 sites in United States
- Volunteers
- 134 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Acute Lymphoblastic Leukemia
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
This research study is for people with a specific type of leukemia called Philadelphia chromosome positive acute lymphoblastic leukemia (the type the patients have).
- Trial name
- NCT00940524
- Testing
- Dasatinib, Mitoxantrone, Cytarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Disease
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin in Hodgkin lymphoma patients treated with…
- Trial name
- BV-ICE (NCT02686346)
- Testing
- Brentuximab Vedotin, Etoposide, Carboplatine
- Where
- 19 sites in Belgium, France
- Volunteers
- 53 people
- Sponsor
- The Lymphoma Academic Research Organisation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Non-Hodgkin's Lymphoma (NHL)
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2…
- Trial name
- NCT00129090
- Testing
- R-CHOEP 14 with 12x Rituximab
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Neuroectodermal Tumor, Brain Metastases
Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases
Primary Objective: Determine the interindividual range and median of individual maximum tolerated doses of valproic acid administered as one time evening dose in conjunction with a dose oral etoposide (50 mg/m2/day for children…
- Conditions
- Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
- Trial name
- NCT00513162
- Testing
- Valproate, Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Disease, Myelodysplastic Syndromes
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).
- Conditions
- Acute Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Myeloproliferative Disorders
- Trial name
- NCT00186342
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide.
- Trial name
- SAHA (NCT00691210)
- Testing
- Vorinostat, Niacinamide, Etoposide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Small Cell Lung Carcinoma
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
PAVE(Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer) is a Greek, investigator- initiated, single arm open- label phase II study of Avelumab in combination with…
- Trial name
- PAVE (NCT03568097)
- Testing
- Avelumab
- Where
- 6 sites in Greece
- Volunteers
- 55 people
- Sponsor
- Hellenic Cooperative Oncology Group
Lymphoma, High-grade
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
The main purpose of the PETAL trial is to determine whether patients with aggressive non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of chemotherapy benefit from a change of the treatment protocol.
- Trial name
- PETAL (NCT00554164)
- Testing
- (R-)CHOP protocol, B-ALL protocol
- Where
- Germany
- Volunteers
- 1,073 people
- Sponsor
- University Hospital, Essen
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00006363
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Small Cell Lung Cancer
Study of BMS-986012 in Subjects With Small Cell Lung Caner
A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer
- Trial name
- NCT02949895
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 2 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb